Another option for HR+ /HER-2 negative pts who failed hormonal therapies, caution to toxicity though esp neutropenia and diarrhea, no OS data yet, will be interesting to know if it worth the adverse events at this stage of disease.
Another use of genomic testing in prostate cancer, pts with high risk mutation may need systemic therapy in addition to oligometastatic stereotactic radiotherapy, well informed patients with no high risk mutation signature may elect to go under surveillance to avoid side effects of androgen deprivation therapy, this also emphasizes the importance of genomic testing in personalizing pt’s care.
Oleclumab (MEDI9447) is a human IgG1λ mAb that inhibits the function of cluster of differentiation 73 (CD73).8 CD73 is an enzyme found on the surfaces of cancer and immune cells and is involved in conversion of adenosine monophosphate to extracellular adenosine, which has an immunosuppressive effect on the tumor environment.9 CD73 upregulation by tumors has been shown to increase extracellular adenosine production and result in subsequent local immunosuppression in multiple canc
Confirming that RR can be an alternative to R chemotherapy as a first line therapy in advanced stage follicular lymphoma.
Coming soon to a pharmacy near you?
Another prognostic marker that can predict added efficacy of therapy in this case bevacizumab.
A benign hematology article, not a large study but an eye opener.
This is not a randomized study, results though can not be ignored since ibrutinib is less toxic than many of the treatments used.
A radiation oncology article, would like to hear comments from our colleagues regarding this, It seems the trend in rad onc that shorter course is better.
Supportive care trial though negative. No role for high dose steroids here.
FCS Hematology Oncology Review creates a platform for our physician network to observe the most recent articles and studies available in the oncology and hematology world. By sharing these articles we are building our wealth of knowledge of new observations and treatments as they come available.
